ES2197792B1 - Formulaciones farmaceuticas que contienen morfina intranasal. - Google Patents

Formulaciones farmaceuticas que contienen morfina intranasal.

Info

Publication number
ES2197792B1
ES2197792B1 ES200150086A ES200150086A ES2197792B1 ES 2197792 B1 ES2197792 B1 ES 2197792B1 ES 200150086 A ES200150086 A ES 200150086A ES 200150086 A ES200150086 A ES 200150086A ES 2197792 B1 ES2197792 B1 ES 2197792B1
Authority
ES
Spain
Prior art keywords
morphine
formulation
formulations containing
pharmaceutical formulations
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES200150086A
Other languages
English (en)
Other versions
ES2197792A1 (es
Inventor
Raja G. Jorge C Achari
Charanjit R. Ramneik Behl
D. Demeireles Vincent
P Dua Anthony
Romeo
Sileno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marina Biotech Inc
Original Assignee
MDRNA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MDRNA Inc filed Critical MDRNA Inc
Publication of ES2197792A1 publication Critical patent/ES2197792A1/es
Application granted granted Critical
Publication of ES2197792B1 publication Critical patent/ES2197792B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulaciones farmacéuticas que contienen morfina intranasal.
Formulación farmacéutica para la administración intranasal que contiene morfina op una sal farmacéuticamente aceptable de la misma, con un pH que oscila entre 3,0 y 7,0, y que en cantidad terapéuticamente eficaz sirve para obtener una respuesta analfésica o anestésica en un mamífero. Dicha formulación puede contener morfina o sal farmacéuticamente aceptable de la misma, en combinación con un sistema de administración nasal, dispersante en una formulación acuosa o no acuosa, suspensiones, soluciones, polvos, geles, ungüentos y cremas. El sistema de administración nasal comprende un tempón para mantener el pH de la morfina o de una sal farmacéuticamente aceptable de la misma, un agente espesante, un humectante, un intensificador de la absorción y combinaciones de los mismos. La formulación comprende además uno o más excipientes farmacéuticos y un conservante.
ES200150086A 1999-06-16 2000-05-23 Formulaciones farmaceuticas que contienen morfina intranasal. Expired - Lifetime ES2197792B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33453799A 1999-06-16 1999-06-16
US09/334537 1999-06-16

Publications (2)

Publication Number Publication Date
ES2197792A1 ES2197792A1 (es) 2004-01-01
ES2197792B1 true ES2197792B1 (es) 2005-05-01

Family

ID=23307687

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200150086A Expired - Lifetime ES2197792B1 (es) 1999-06-16 2000-05-23 Formulaciones farmaceuticas que contienen morfina intranasal.

Country Status (30)

Country Link
US (1) US6677346B1 (es)
EP (2) EP1183027A4 (es)
JP (1) JP2003501467A (es)
KR (1) KR20020016831A (es)
AU (1) AU774175B2 (es)
BG (1) BG106221A (es)
BR (1) BR0012082A (es)
CA (1) CA2374877C (es)
CZ (1) CZ20014399A3 (es)
DE (1) DE10084709T1 (es)
DK (1) DK200101859A (es)
EE (1) EE200100677A (es)
ES (1) ES2197792B1 (es)
FI (1) FI20012462A (es)
GB (1) GB2367005A (es)
HR (1) HRP20010926A2 (es)
HU (1) HUP0201856A3 (es)
IS (1) IS6202A (es)
LT (1) LT4976B (es)
LU (1) LU90859B1 (es)
LV (1) LV12859B (es)
MX (1) MXPA01012879A (es)
NO (1) NO20015931L (es)
NZ (1) NZ515783A (es)
PL (1) PL352556A1 (es)
SE (1) SE0104203D0 (es)
SI (1) SI20850A (es)
SK (1) SK18172001A3 (es)
TR (1) TR200103613T2 (es)
WO (1) WO2000076506A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
AU2001291159A1 (en) * 2000-09-20 2002-04-02 Shahinian Jr., Lee Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
AU2002303148A1 (en) * 2001-06-29 2003-03-03 Leon J. Lewandowski Individualized addiction cessation therapy
GB0210264D0 (en) * 2002-05-03 2002-06-12 Arakis Ltd The treatment of pain and migraine headache
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
WO2006058022A1 (en) 2004-11-24 2006-06-01 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US9415034B2 (en) * 2005-01-05 2016-08-16 National Defense Medical Center Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B)
ES2277743B2 (es) * 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
US20090317377A1 (en) 2005-08-26 2009-12-24 Yeomans David C Therapy procedure for drug delivery for trigeminal pain
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
BRPI0720434A2 (pt) * 2006-12-22 2014-01-07 Sigma Tau Ind Farmaceuti Gel útil para liberação de fármacos oftálmicos
GB2477545B (en) * 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
SG194927A1 (en) 2011-05-13 2013-12-30 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
AU2012386221A1 (en) 2012-07-26 2015-02-26 Wockhardt Limited Pharmaceutical composition comprising diamorphine for intranasal administration
EP3082817A4 (en) * 2013-12-18 2017-06-21 Aegis Therapeutics, LLC Compositions for drug administration
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP4331670A3 (en) 2015-01-07 2024-05-29 Tonix Pharma Limited Magnesium-containing oxytocin formulations and methods of use
EP3528873A2 (en) * 2016-10-21 2019-08-28 Somniferum Labs LLC Apparatus for controlled delivery of opioid and other medications
EP3697381B1 (en) * 2017-10-20 2023-06-07 Chiesi Farmaceutici S.p.A. Pharmaceutical formulations comprising opioid receptor agonist as active ingredients, methods of manufacture and therapeutic uses thereof
WO2019157099A1 (en) 2018-02-06 2019-08-15 Aegis Therapeutics, Llc Intranasal epinephrine formulations and methods for the treatment of disease
CN115804754A (zh) * 2022-12-16 2023-03-17 广州新济药业科技有限公司 吗啡鼻喷剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4464376A (en) 1982-07-22 1984-08-07 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
WO1994022445A2 (en) * 1993-03-26 1994-10-13 Merkus Franciscus W H M Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
EP1006969A1 (en) * 1996-09-27 2000-06-14 Nastech Pharmaceutical Co. Intranasal formulations for promoting sleep and method of using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VERWEIJ, S.L. et al. Can morphine be administered nasally?. Ziekenhuisfarmacie, 1988, nº 4, páginas 73-77. *

Also Published As

Publication number Publication date
EE200100677A (et) 2003-02-17
PL352556A1 (en) 2003-08-25
HUP0201856A3 (en) 2004-12-28
US6677346B1 (en) 2004-01-13
NO20015931D0 (no) 2001-12-04
SE0104203L (sv) 2001-12-14
CA2374877C (en) 2004-04-13
LT2001119A (en) 2002-07-25
KR20020016831A (ko) 2002-03-06
IS6202A (is) 2001-12-14
HUP0201856A1 (en) 2002-09-28
EP1419774A1 (en) 2004-05-19
DE10084709T1 (de) 2002-09-26
BG106221A (en) 2002-08-30
AU774175B2 (en) 2004-06-17
ES2197792A1 (es) 2004-01-01
FI20012462A (fi) 2002-01-16
TR200103613T2 (tr) 2004-08-23
JP2003501467A (ja) 2003-01-14
EP1183027A4 (en) 2003-02-05
LV12859B (en) 2002-12-20
CA2374877A1 (en) 2000-12-21
BR0012082A (pt) 2002-05-07
GB0128383D0 (en) 2002-01-16
SE0104203D0 (sv) 2001-12-14
LU90859B1 (en) 2002-01-24
SK18172001A3 (sk) 2002-07-02
LT4976B (lt) 2002-12-30
NO20015931L (no) 2002-02-08
HRP20010926A2 (en) 2003-04-30
EP1183027A1 (en) 2002-03-06
WO2000076506A1 (en) 2000-12-21
CZ20014399A3 (cs) 2002-06-12
MXPA01012879A (es) 2003-06-24
GB2367005A (en) 2002-03-27
SI20850A (sl) 2002-10-31
DK200101859A (da) 2001-12-12
AU5156100A (en) 2001-01-02
NZ515783A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
ES2197792B1 (es) Formulaciones farmaceuticas que contienen morfina intranasal.
DK1126830T3 (da) Farmaceutiske præparater til ekstern anvendelse indeholdende ikke-steroide anti-inflammatoriske og analgetiske midler
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
CY1114000T1 (el) Σταθεροποιημενα διαλυματα τεριπαρατιδης
ES2094694B1 (es) Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
ES2193515T3 (es) Composicion farmaceutica que comprende un compuesto triciclico con mejor estabilidad, absortividad y escaso potencial irritativo.
NL300281I2 (nl) Exenatide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
IT8821324A0 (it) Composizioni farmaceutiche ad attivita' analgesica ed antiinfiammatoria per uso orale, dotate di ottima palatabilita' ed esenti da effetti irritanti sulle mucose.
WO2001041550A3 (en) Topical anesthetic formulation
AR027554A1 (es) Nuevo sistema de adminstracion de farmacos autoemulsionante
HUP0001739A2 (hu) Gyógyászati hatóanyagok behatolását fokozó oldószerrendszert tartalmazó helyileg alkalmazott készítmények, valamint pufferolt oldószerrendszer alkalmazása
NO943070L (no) Antitussiva
DK0647129T3 (da) Præparat til topisk anvendelse
AR031010A1 (es) Una composicion farmaceutica, util para inhibir el dano celular
PE20030092A1 (es) Formulacion de una solucion de inhalacion con una sal de tiotropio
ATE316376T1 (de) Neue pharmazeutische zusammenstellung und deren herstellungsprozess
SE8009102L (sv) Estrar av l-arginin for anvendning vid behandling av akut lungodem, vissa chocktillstand och hyperfibrinolys
DK0593562T3 (da) Topisk præparat indeholdende penciclovir
AR030647A1 (es) Composicion farmaceutica con actividad de agua especifica
DE60135845D1 (de) Pralmorelin-haltige nasentropfen-präparate
MX9601756A (es) Composicion liquida estable que contiene urato-oxidasa, y composicion liofilizada para su preparacion.
ES2135424T3 (es) Composicion oral a base de ibuprofeno.
KR960021046A (ko) 카페익산을 포함하는 b형 간염 치료제
TH20307A (th) สารสูตรผสมอิมัลชันชนิดใหม่

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20040101

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2197792B1

Country of ref document: ES

FA2A Application withdrawn

Effective date: 20051018